Search Results
Found 1 results
510(k) Data Aggregation
(746 days)
InActiv Blue
InActiv Blue is intended for the stabilization, transportation and inactivation of upper respiratory specimens suspected of containing SARS-CoV-2. These devices can be used for collection transport and storage of specimens at refrigerated (2-8°C) or ambient temperatures (20-25°C). SARS-CoV-2 RNA in the specimens is stabilized for 7 days at these specified temperatures. Specimens collected and stored in an InActiv Blue collection tube are suitable for use with legally marketed molecular diagnostic devices.
InActiv Blue is a virus-inactivating and lysis solution that abrogates the infectious potential of the collected material without affecting the integrity of the RNA. Two milliliters of InActiv Blue solution are provided in a polypropylene flat bottom collection tube with a high-density polyethylene (HDPE) cap (product code IB TUB). The device is non-sterile, single use. Secondary Packaging for the collection tube configuration includes racks of 50 collection tubes and cardboard boxes with either 400 or 1200 collection tubes.
Sample types intended for collection with the device include upper respiratory swab samples. Swabs are not provided with the InActiv Blue collection tubes.
The active components of the InActiv Blue solution are guanidine thiocyanate, Nlauroylsarcosine sodium salt and EDTA. These components are formulated in a sodium phosphate buffered solution containing methylene blue.
This document describes the performance of the InActiv Blue device, a microbial nucleic acid storage and stabilization device, for stabilizing and inactivating SARS-CoV-2 in upper respiratory specimens.
Here's the breakdown of the acceptance criteria and the study results:
1. Acceptance Criteria and Reported Device Performance
Acceptance Criteria (Not explicitly stated as "acceptance criteria" but inferred from study outcomes) | Reported Device Performance |
---|---|
Shelf-Life Stability: | |
Maintain product integrity (pH, osmolarity, appearance, evaporation) for the claimed shelf-life. | Met all stability specifications for 21 months: pH (6 +/- 0.6), osmolarity (4200 +/- 420 mOsm/kg), and visual appearance (PASS) and evaporation (PASS). |
Limit of Detection (LOD): | |
High probability of detection at a specified viral concentration (e.g., 95% positivity). | 100% positive at 45 particles/mL and 90% positive at 15 particles/mL. LOD determined as 45 particles/mL. |
Sample Stability (SARS-CoV-2 RNA): | |
SARS-CoV-2 RNA in specimens collected and stored in InActiv Blue should be stable for 7 days at refrigerated (2-8°C) or ambient (20-25°C) temperatures, with minimal Ct value shift. | All samples remained within 3 Ct of the initial reading after 7 days at both 2-8°C and 20-25°C, across multiple product lots. |
Viral Inactivation: | |
Significant reduction in infectivity of SARS-CoV-2. | Log infectivity reduction factor of at least 3.89 logs for three different lots of InActiv Blue after 1, 2.5, and 5 minutes of exposure. This demonstrates substantial viral inactivation. |
2. Sample Size and Data Provenance
The provided document does not explicitly delineate a "test set" in the context of an algorithm or AI device as it describes a physical collection device. However, the sample sizes and data provenance for the performance studies are detailed:
- Shelf-Life Stability: At least eight lots of InActiv Blue were used. Samples were stored at room temperature (15-25°C). The study appears to be retrospective in terms of analyzing existing product lots over time. The country of origin of the data is not specified, but the applicant (FertiPro NV) is based in Belgium.
- Limit of Detection (LOD):
- Preliminary LOD: SARS-CoV-2 at 5 concentrations (5, 15, 45, 135, 405 particles/mL), each performed in triplicate. Total 15 preliminary tests.
- Confirmatory LOD: For each concentration (15 and 45 particles/mL), 20 replicates were evaluated. Total 40 confirmatory tests.
- The matrix used was "nasopharyngeal clinical matrix" spiked with SARS-CoV-2. The data provenance (country, retrospective/prospective) is not explicitly stated.
- Sample Stability Study: Six replicate samples containing nasopharyngeal matrix were used for each of the four lots of InActiv Blue tested (newly manufactured, middle-aged, near/recently expired, and stressed). Three replicates from each lot were stored at 2-8°C and three at 20-25°C. Total of 24 replicates (4 lots x 6 replicates). The matrix was "nasopharyngeal matrix" spiked with SARS-CoV-2. Data provenance is not explicitly stated.
- Viral Inactivation: Three lots of InActiv Blue (near expiration) were used. For each lot, the study involved mixing virus stock 1:1 with InActiv Blue and incubating for 1, 2.5, and 5 minutes. No specific "sample size" of individual viral samples is mentioned beyond the use of 3 lots and multiple exposure times for each. Data provenance is not explicitly stated.
3. Number of Experts and Qualifications for Ground Truth
This information is not applicable as the device is a physical sample collection and stabilization device, not an AI or imaging device requiring expert interpretation for ground truth establishment. The ground truth for the performance studies (e.g., viral load, RNA integrity) is established through laboratory assays (e.g., Roche cobas SARS-CoV-2 assay) and cell culture methods.
4. Adjudication Method for Test Set
This information is not applicable. The studies described are laboratory performance studies, not clinical studies requiring adjudications of diagnoses or interpretations by experts.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
This information is not applicable. This device is not an AI or imaging device used by human readers, so an MRMC comparative effectiveness study is not relevant.
6. Standalone (Algorithm Only) Performance
This information is not applicable. The InActiv Blue is a physical medical device, not an algorithm, so the concept of "standalone performance" for an algorithm does not apply.
7. Type of Ground Truth Used
The ground truth used for these studies is scientific and laboratory-based:
- Shelf-Life Stability: Physical and chemical properties of the solution (pH, osmolarity, visual inspection, evaporation) against predefined specifications.
- Limit of Detection: Quantification of viral particles (SARS-CoV-2) using a legally marketed molecular diagnostic device (Roche cobas SARS-CoV-2 assay) and determining the concentration at which a specified percentage of positive results are achieved.
- Sample Stability: Detection and quantification of SARS-CoV-2 RNA using a molecular diagnostic device (Roche cobas SARS-CoV-2 assay) and monitoring the change in Ct values over time, demonstrating RNA integrity.
- Viral Inactivation: Measurement of residual infectivity of SARS-CoV-2 using cell culture (Vero E6 cells) and determining the cytopathic effect and TCID50 (Tissue Culture Infectious Dose 50%) via the Reed and Muench method to quantify log reduction in infectivity.
8. Sample Size for the Training Set
This information is not applicable. This device is a physical collection and stabilization device and does not involve AI or machine learning models that require a training set. The development of such a device relies on chemical formulation, engineering, and manufacturing process control, rather than data-driven algorithm training.
9. How the Ground Truth for the Training Set Was Established
This information is not applicable as there is no training set for this type of device.
Ask a specific question about this device
Page 1 of 1